Influence of Vibroacoustic Therapy Modes on the Course of Coronavirus Infection

NCT ID: NCT05143372

Last Updated: 2024-02-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-09

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assessment of the dynamics of changes in physical, instrumental and laboratory parameters in patients with identified coronavirus infection complicated by acute respiratory failure included in the study in accordance with the inclusion criteria, and comparison of the results with the control group, study of the effect of modes when using vibroacoustic lung therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Acute Respiratory Failure Vibration; Exposure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SaO2 (oxygen status)

Measurment 4 times per day, ABA (acid-bases analyses)

Group Type ACTIVE_COMPARATOR

Vibrolung

Intervention Type DEVICE

Vibroacoustic respiratory therapy

PaO2/FiO2 (respiratory index)

Measurment 4 times per day, ABA (acid-bases analyses)

Group Type ACTIVE_COMPARATOR

Vibrolung

Intervention Type DEVICE

Vibroacoustic respiratory therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vibrolung

Vibroacoustic respiratory therapy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults
* P/F less 300 torr
* COVID-19 Virus Infection

Exclusion Criteria

* children
* acute stroke
* acute coronary syndrome
* DVT
* implanted pacemaker
* rib fracture
* infection on chest
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Astana Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aidos Konkayev

professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NATIONAL CENTER Scientific Center of Traumatology and Orthopedics named after Academician Batpenov N.D.

Astana, , Kazakhstan

Site Status

Multidisciplinary city hospital No. 3 of Nursultan

Astana, , Kazakhstan

Site Status

Multidisciplinary Infectious Diseases Hospital of Nursultan

Astana, , Kazakhstan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Kazakhstan

References

Explore related publications, articles, or registry entries linked to this study.

Konkayev A, Bekniyazova A. Vibroacoustic therapy in the treatment of patients with COVID-19 complicated by respiratory failure: a pilot randomized controlled trial. Front Med (Lausanne). 2023 Dec 14;10:1225384. doi: 10.3389/fmed.2023.1225384. eCollection 2023.

Reference Type DERIVED
PMID: 38155668 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

СТЛ-000215

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Inhaled Polymyxin E to Prevent VAP
NCT06819462 NOT_YET_RECRUITING NA
UVA Light Device to Treat COVID-19
NCT04572399 COMPLETED NA